If physicians had the ability to observe patients’ biological function at the cellular level, could detect cancer months and even years earlier than current diagnostic tests with higher accuracy, and could monitor and personalize cancer treatment in real time, what would it do to the practice of oncology?

More importantly, what would it mean for cancer patients?

Using our patent-pending VeraMarker™ metabolite profiling technology platform, Matrix-Bio is developing a portfolio of diagnostic tests for cancer screening, recurrence monitoring, and treatment monitoring that are more accurate, detect cancer earlier, and yield far fewer false positives than tests currently on the market. Our metabolite profiling diagnostic tests require a simple blood draw, making them easy to implement from both practice and patient perspectives. Our goal is to provide oncologists with more effective, highly accurate diagnostic tools that redefine cancer detection, support earlier diagnosis, provide a better quality of life for patients from less drug treatment toxicity, and reduce cancer morbidity.

Matrix-Bio’s metabolite profiling technology is uniquely suited to cancer diagnostics as it identifies subtle perturbations in cellular metabolism that can be detected in blood and used to identify the presence or absence of diseases such as cancer with an exceptionally high degree of sensitivity and specificity.

We are currently focused on developing both a liver cancer diagnostics test and a colon cancer recurrence monitoring test. Here is an update:


VeraMarker™ LCS (Liver Cancer Screening) Test

According to the American Cancer Society, there will be 33,190 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States in 2014; about 23,000 people will die of these cancers. Globally, liver cancer is the most common form of cancer and the leading cause of cancer deaths. In 2014, an estimated 600,000 people worldwide will die of liver cancer. One of the reasons is that liver cancer is often detected in later stages. Current tests are often not sensitive enough to detect early stage liver cancer.

Matrix-Bio is currently developing a VeraMarker™ Liver Cancer Screening (LCS) test intended to detect liver cancer in its earliest stages when it is more treatable. Additionally, the test can be used as a surveillance test for high-risk patients with Hepatitis C or Hepatitis B with cirrhosis. Up to five percent of these patients develop liver cancer within a year. Current screening tests for liver cancer are not sufficiently reliable for early detection. In prospective clinical studies, Matrix-Bio’s LCS test exhibits more than 95 percent accuracy.


VeraMarker™ CCM (Colon Cancer Monitoring) Test

An estimated three million CEA tests are ordered by oncologists to monitor colon cancer patients each year. Yet the CEA test is inadequate as it often misses recurrence, detects cancer in later stages or yields false positives. Matrix-Bio’s CCM test is highly sensitive and able to detect cancer recurrence 11+ months earlier than current tests. Currently in development and primary focus of the company, Matrix-Bio plans to launch the metabolite profiling-based CCM test as an adjunct to the CEA test to accelerate adoption. The CCM test will utilize existing CPT codes for CEA for reimbursement pending a unique CPT code.

VeraMarker™ CCS (Colon Cancer Screening) Test

The American Cancer Society estimates there are around 102,500 new cases of colon cancer each year. Despite being among the easiest cancers to diagnose, it is often found in later, more difficult to treat stages. Matrix-Bio is developing a CCS test to support earlier, more accurate diagnosis of colon cancer.

Register for updates on our liver cancer and colon cancer diagnostic tests using metabolite profiling.



If you have questions about Matrix-Bio’s early liver cancer detection test or about our investing and partnership opportunities, please contact:

Eric Beier, MD, MBA